SCHEMBL6330265

SCHEMBL6330265

Cc1ccc(S(=O)(=O)c2c(C)[nH]c(/C=C3\C(=O)Nc4cc(Br)ccc43)c2CCC(=O)O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 16/20 0.59
FGFR1 P11362 15/20 0.59
PDGFRB P09619 13/20 0.59
EGFR P00533 5/20 0.53
AURKA O14965 5/20 0.51
FLT3 P36888 3/20 0.51
RET P07949 2/20 0.51
FLT1 P17948 2/20 0.51
MAP4K2 Q12851 2/20 0.51
STK3 Q13188 2/20 0.51
AURKB Q96GD4 2/20 0.51
FLT4 P35916 2/20 0.51
GAK O14976 1/20 0.51
RPS6KA5 O75582 1/20 0.51
RPS6KA4 O75676 1/20 0.51
LATS1 O95835 1/20 0.51
CSNK2A2 P19784 1/20 0.51
MAP2K2 P36507 1/20 0.51
ZAP70 P43403 1/20 0.51
MAP2K1 Q02750 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6330065 0.93 KDR (0.57) KDRFGFR1PDGFRBEGFRAURKA
SCHEMBL6329246 0.93 FGFR1 (0.69) KDRFGFR1PDGFRBEGFRAURKA
SCHEMBL6328172 0.89 KDR (0.65) KDRFGFR1PDGFRBEGFRAURKA
SCHEMBL6326141 0.88 KDR (0.70) KDRFGFR1PDGFRBEGFRAURKA
SCHEMBL6329036 0.88 FGFR1 (0.67) KDRFGFR1PDGFRBEGFRAURKA
SCHEMBL6327589 0.87 FGFR1 (0.70) KDRFGFR1PDGFRBEGFRAURKA
SCHEMBL6327970 0.87 FGFR1 (0.61) KDRFGFR1PDGFRBEGFRAURKA
SCHEMBL6333702 0.87 FGFR1 (0.67) KDRFGFR1PDGFRBEGFRAURKA
SCHEMBL6329239 0.86 FGFR1 (0.64) KDRFGFR1PDGFRBEGFRAURKA
SCHEMBL6328908 0.85 AURKA (0.68) KDRFGFR1PDGFRBEGFRAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032871-A1 Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors SUGEN, INC. 2005-02-10 US claimed
US-20050032871-A1 Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors SUGEN, INC. 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032871-A1 Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors MAP3K20, CDK20, STK10 KDR 974/4885FGFR1 382/4885PDGFRB 472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.